Skip to main content
TipRanks
Go Ultimate75% OFF

Newmed Energ Pu (NWMD) AI Stock Analysis

7 Followers
IL:NWMD

Newmed Energ Pu

(TASE:NWMD)

Select Model
Rating:65Neutral
Price Target:ILA 1,822.00â–²(7.49% Upside)
Action:reiterated
Date:11/20/26

Newmed Energ Pu's overall score is strongly supported by highly positive earnings momentum, including a 35% production increase and exceptional core operating margins. However, these fundamental strengths are counterbalanced by emerging financial risks, notably a sharp drop in free cash flow and a recent spike in debt levels. Furthermore, a relatively premium valuation and a stock price that remains below its 200-day moving average temper the overall rating.

Positive Factors
Production and Revenue GrowthProduction and revenue acceleration indicates stronger utilization of the asset base and expanding market reach across Israel, Egypt and Jordan. If sustained, higher volumes can improve operating leverage and support cash generation as additional capacity becomes available.
Negative Factors
Elevated LeverageNet debt of about $1.4B and debt-to-equity near 1.0 represent materially higher leverage than 2025. The June 2027 bond maturity and reliance on available facilities can constrain capital allocation and reduce resilience while large projects require funding.

Newmed Energ Pu (NWMD) vs. iShares MSCI Israel ETF (EIS)

-10%0%10%20%30%40%IL:NWMD+8.20%EIS+4.94%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 19.93B
Dividend Yield
3.73%
Average Volume (3M)
1.06M
Price to Earnings (P/E)
23.9
Beta (1Y)
1.09
Revenue Growth
-9.32%
EPS Growth
-45.02%
Country
Israel
Employees
24
Sector
Energy
Sector Strength
65
Industry
Oil & Gas Exploration & Production

Newmed Energ Pu Business Overview & Revenue Model

Company Description

NewMed Energy - Limited Partnership is an energy firm engaged in the exploration, development, production, and commercialization of petroleum, natural gas, and condensate, primarily operating in Israel and Cyprus. The company holds significant intere...

How the Company Makes Money

Newmed Energy makes money primarily by producing and selling natural gas (and, where applicable, associated hydrocarbons) from its upstream oil & gas interests. Its core revenue model is based on: (1) Sales of produced natural gas under contractual a...

Newmed Energ Pu Earnings Call Summary

Earnings Call Date:Aug 06, 2026(Q2-2026)|% Change Since:5.57%|Next Earnings Date:May 26, 2024
Earnings Call SentimentPositive

The call presented multiple strong operational and financial improvements: production increased ~35%, revenues rose ~53% and net income ~44%, supported by higher gas prices and completed midstream works. Material infrastructure milestones (third pipeline, Ashdod–Ashkelon looping) and progress on major growth projects (Leviathan expansion on schedule, Aphrodite progressing toward FID) provide clear upside. Offsetting considerations include rising operating costs (+$21M), higher finance expenses (+$26M), net debt of ~$1.4B with an upcoming bond maturity in 2027, and some benefits that are timing‑lagged or accrue to partners rather than immediately to NewMed. Overall, positive momentum and meaningful value catalysts outweigh the noted financial and timing challenges.

Positive Updates

Strong Production Growth
Q2 2026 production of ~2.7 Bcm vs 2.0 Bcm in Q2 2025, an increase of ~0.7 Bcm (+35%). All three markets (Israel, Egypt, Jordan) grew, with Egyptian volumes increasing by ~0.5 Bcm in the quarter.

Negative Updates

Rising Operating Costs and Depreciation
Costs and expenses increased by ~$21M year‑over‑year, mainly from higher operations costs and depreciation, partially offsetting revenue gains.

Company Guidance

Management guided that Q2‑2026 results included production of 2.7 Bcm (vs. 2.0 Bcm in Q2‑2025, with ~+0.5 Bcm to Egypt), revenues of $293M (vs. $191M), net profit of ~$117–118M, average gas price $6.5/MMBtu (vs. $5.6), and a $60M dividend; net revenues rose ~$86M (≈$59M from higher production, $25M from higher price, $2.1M condensate) partially offset by ~$21M higher costs and ~$26M higher finance expenses, plus $6.8M other revenues and $7.7M discontinued‑operation income. Liquidity/financial guidance: net debt ≈$1.4B, $550M available bank facilities, ~$95M of bond buybacks to date, next bond maturity June‑2027. Capex/project guidance: third pipeline lifts peak capacity to 15.8 Bcm/year (from ~14.5, +1 Bcm), Ashdod–Ashkelon looping adds ~2 Bcm/year (allocated to Leviathan partners), Leviathan Phase‑1b on track for H2‑2029 with total cost ~$2.4B and ~23% complete and a rig to drill 3 wells by year‑end; FAJR+compression due EOY, Nitzana ahead of Phase‑2, Aphrodite FID targeted H1‑2027, and upcoming seismic surveys including a ~5,000‑node OBN survey.

Newmed Energ Pu Financial Statement Overview

Summary

The score reflects exceptional profitability with an 82.9% EBITDA margin and steady historical equity growth. However, this is significantly weighed down by recent net income contraction, a severe drop in free cash flow to $158.5 million, and a spike in total debt pushing leverage above 1.0x.

Income Statement

68Positive

Balance Sheet

65Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Mar 2024Dec 2022Dec 2021
Income Statement
Total Revenue949.33M938.07M1.14B934.60M1.14B882.50M
Gross Profit640.92M585.08M718.10M780.70M701.70M518.10M
EBITDA787.21M760.65M874.80M782.70M872.10M657.20M
Net Income300.36M371.29M524.60M433.60M469.70M404.90M
Balance Sheet
Total Assets4.66B3.97B3.99B3.85B3.94B3.85B
Cash, Cash Equivalents and Short-Term Investments691.82M157.53M384.50M186.70M418.30M340.85M
Total Debt2.03B1.12B1.63B1.82B2.16B2.22B
Total Liabilities2.68B2.08B2.21B2.33B2.65B2.91B
Stockholders Equity1.98B1.89B1.79B1.51B1.29B938.54M
Cash Flow
Free Cash Flow158.52M304.72M463.30M423.10M405.80M423.25M
Operating Cash Flow498.79M547.08M577.50M559.50M504.70M453.64M
Investing Cash Flow-485.15M30.20M-114.20M36.10M-273.50M982.04M
Financing Cash Flow352.39M-516.12M-441.20M-588.90M-429.10M-1.29B

Newmed Energ Pu Technical Analysis

Technical Analysis SentimentNeutral
Last Price1695.00

Price Trends

50DMA1646.78Positive
100DMA1634.81Positive
200DMA1740.66Negative

Market Momentum

MACD29.46Negative
RSI52.51Neutral
STOCH60.74Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NWMD, the sentiment is Neutral. The current price of 1695.00 is above the 20-day moving average (MA) of 1670.60, above the 50-day MA of 1646.78, and below the 200-day MA of 1740.66, indicating a neutral trend. The MACD of 29.46 indicates Negative momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 60.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:NWMD.

Newmed Energ Pu Peers Comparison

Overall Rating

UnderperformOutperform
Sector (65)

Financial Indicators

IL:NWMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *65Neutral$15.17B7.614.09%5.20%3.87%-62.32%
IL:NWMDIL:NWMD65NeutralILS 20.08B23.8915.86%3.73%-9.32%-45.02%
IL:DLEKGIL:DLEKG64NeutralILS 14.17B4.1635.13%5.29%-37.24%-73.95%
IL:TMRPIL:TMRP63NeutralILS 2.08B14.72―15.86%-15.98%-22.66%
IL:TOENIL:TOEN62NeutralILS 282.61M14.74―36.32%-1.64%9.82%
IL:NVPTIL:NVPT54NeutralILS 14.80B14.47―3.29%920.97%―

* Energy Sector Average

Performance Comparison

-20%0%20%IL:NWMDIL:DLEKGIL:ISRAIL:TOENIL:TMRPIL:NVPTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IL:NWMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:NWMDNewmed Energy Limited Partnership1695.00128.448.20%
IL:DLEKGDelek Group 7780.00-490.92-5.94%
IL:ISRAIsramco Negev 2 LP220.3010.474.99%
IL:TOENTomer Energy Royalties (2012) Ltd.1380.00-378.04-21.50%
IL:TMRPTamar Petroleum Ltd.2570.00-618.94-19.41%
IL:NVPTNavitas Petroleum LP11990.00507.924.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026